These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28878690)

  • 21. [Enhanced Ca2+-sensing receptor function in pulmonary hypertension].
    Yamamura A; Yamamura H; Yuan JX
    Yakugaku Zasshi; 2013; 133(12):1351-9. PubMed ID: 24292183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating pulmonary arterial hypertension: current treatments and future prospects.
    Raja SG; Raja SM
    Ther Adv Chronic Dis; 2011 Nov; 2(6):359-70. PubMed ID: 23251761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Signal Mechanisms of Vascular Remodeling in the Development of Pulmonary Arterial Hypertension.
    Li MX; Jiang DQ; Wang Y; Chen QZ; Ma YJ; Yu SS; Wang Y
    J Cardiovasc Pharmacol; 2016 Feb; 67(2):182-90. PubMed ID: 26448276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
    Orriols M; Gomez-Puerto MC; Ten Dijke P
    Cell Mol Life Sci; 2017 Aug; 74(16):2979-2995. PubMed ID: 28447104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges.
    Lajoie AC; Bonnet S; Provencher S
    Pulm Circ; 2017; 7(2):312-325. PubMed ID: 28597774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Novel concepts in the pathobiology of pulmonary arterial hypertension].
    Rosenkranz S
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S167-9. PubMed ID: 18814087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists.
    Madonna R; Cocco N; De Caterina R
    Cardiovasc Drugs Ther; 2015; 29(5):469-79. PubMed ID: 26145170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction.
    Gomez-Arroyo J; Sandoval J; Simon MA; Dominguez-Cano E; Voelkel NF; Bogaard HJ
    Ann Am Thorac Soc; 2014 Sep; 11(7):1101-15. PubMed ID: 25079379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unraveling endothelin-1 induced hypercontractility of human pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension.
    Wilson JL; Warburton R; Taylor L; Toksoz D; Hill N; Polgar P
    PLoS One; 2018; 13(4):e0195780. PubMed ID: 29649319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors.
    Fukumoto Y; Tawara S; Shimokawa H
    Tohoku J Exp Med; 2007 Apr; 211(4):309-20. PubMed ID: 17409670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug therapy of pulmonary arterial hypertension in 2014].
    Aschermann M; Jansa P
    Vnitr Lek; 2014 Apr; 60(4):282-8. PubMed ID: 24985985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteoprotegerin Disruption Attenuates HySu-Induced Pulmonary Hypertension Through Integrin αvβ3/FAK/AKT Pathway Suppression.
    Jia D; Zhu Q; Liu H; Zuo C; He Y; Chen G; Lu A
    Circ Cardiovasc Genet; 2017 Feb; 10(1):. PubMed ID: 28077433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Updated treatment algorithm of pulmonary arterial hypertension.
    Galiè N; Corris PA; Frost A; Girgis RE; Granton J; Jing ZC; Klepetko W; McGoon MD; McLaughlin VV; Preston IR; Rubin LJ; Sandoval J; Seeger W; Keogh A
    J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D60-72. PubMed ID: 24355643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular interplay in pulmonary arterial hypertension: implications for new therapies.
    Nogueira-Ferreira R; Ferreira R; Henriques-Coelho T
    Biochim Biophys Acta; 2014 May; 1843(5):885-93. PubMed ID: 24491811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension.
    Schwenke DO; Pearson JT; Sonobe T; Ishibashi-Ueda H; Shimouchi A; Kangawa K; Umetani K; Shirai M
    J Appl Physiol (1985); 2011 Apr; 110(4):901-8. PubMed ID: 21212241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension.
    Humbert M; Montani D; Perros F; Dorfmüller P; Adnot S; Eddahibi S
    Vascul Pharmacol; 2008; 49(4-6):113-8. PubMed ID: 18606248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Key role of the RhoA/Rho kinase system in pulmonary hypertension.
    Connolly MJ; Aaronson PI
    Pulm Pharmacol Ther; 2011 Feb; 24(1):1-14. PubMed ID: 20833255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension.
    Maruyama H; Dewachter C; Belhaj A; Rondelet B; Sakai S; Remmelink M; Vachiery JL; Naeije R; Dewachter L
    J Heart Lung Transplant; 2015 Mar; 34(3):468-78. PubMed ID: 25447587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
    Cheng G; Wang X; Li Y; He L
    Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration.
    Pullamsetti S; Krick S; Yilmaz H; Ghofrani HA; Schudt C; Weissmann N; Fuchs B; Seeger W; Grimminger F; Schermuly RT
    Respir Res; 2005 Nov; 6(1):128. PubMed ID: 16262900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.